OLIVIANA GEAVLETE

Dr. OLIVIANA GEAVLETE

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in Heart Failure Reviews
Verified
Journal Article
Open access
PDF file
OGOLIVIANA GEAVLETE
OLIVIANA GEAVLETE
SCSean P. Collins
Sean P. Collins
AMAlexandre Mebazaa
Alexandre Mebazaa
LYLinda Ye
Linda Ye
APAlberto Palazzuoli
Alberto Palazzuoli
OCOvidiu Chioncel
Ovidiu Chioncel
Hypertensive acute heart failure (HT-AHF) has historically been recognized as a distinct clinical phenotype of AHF, characterized by acute pulmonary congestion in the context of elevated systolic blood pressure (SBP), typically > 140 mmHg. However, emerging evidence has begun to challenge the diagnostic accuracy, clinical utility, and relevance of this category. A main criticism of HT-AHF is its considerable overlap with other AHF clinical profiles, including acute decompensated heart failure (ADHF) and acute pulmonary oedema (APO). Clinical features such as dyspnea and pulmonary congestion are not unique to HT-AHF. Additionally, some HT-AHF patients concurrently fulfill diagnostic criteria for the ADHF phenotype, including a history of HF or signs of volume overload, leading to ambiguity in diagnosis. HT-AHF is associated with very low in-hospital mortality (0–2%) compared to other AHF phenotypes. Notably, there is no robust evidence linking high SBP to poor short- or long-term outcomes, nor are there randomized clinical trials validating distinct management strategies for HT-AHF. Often associated with the management of HT-AHF, vasodilators have shown limited benefit across trials, contributing to a downgrade in guideline recommendations. The relatively favorable short-term prognosis and the lack of a standardized, evidence-based treatment approach weaken the rationale for classifying HT-AHF as a standalone AHF category. Given the heterogeneity of clinical presentations, overlap with other AHF phenotypes, and lack of prognostic distinction or targeted therapy, the term “AHF with high SBP at presentation” offers a more flexible and clinically meaningful descriptor, encouraging a more nuanced approach to treatment.

Verified
Journal Article
Open access
PDF file
MVMihajlo Viduljevic
Mihajlo Viduljevic
MPMarija M. Polovina
Marija M. Polovina
OGOLIVIANA GEAVLETE
OLIVIANA GEAVLETE
MAMarianna Adamo
Marianna Adamo
AHAdi Hadzibegovic
Adi Hadzibegovic
PSPetar M. Seferović
Petar M. Seferović
Right ventricular (RV) dysfunction is common and linked to poor outcomes across conditions such as heart failure (HF), acute coronary syndromes, pulmonary embolism, and pulmonary hypertension. While imaging, electrocardiogram (ECG), and invasive tests remain central to RV assessment, circulating biomarkers offer a rapid, non-invasive, and reliable alternative. These biomarkers reflect key pathophysiological processes, including myocardial injury, stress, fibrosis, inflammation, congestion, and multiorgan involvement. High-sensitivity troponins and natriuretic peptides (BNP, NT-proBNP) are already widely used, while emerging biomarkers—such as CA125, copeptin, galectin-3, and others—may enhance diagnostic accuracy and risk stratification. Some, like CA125 and NT-proBNP, have shown promise in guiding post-discharge therapy. However, challenges remain regarding the specificity of biomarkers for RV dysfunction and their role across different clinical contexts. This review provides an integrated overview of RV dysfunction, with a focus on the diagnostic and therapeutic potential of both established and novel biomarkers.

1 July 2026 in Cardiac Failure Review
Verified
Journal Article
Open access
RIRadu Razvan Ilie
Radu Razvan Ilie
BDBeth Davison
Beth Davison
SCSean P Collins
Sean P Collins
AMAlexandre Mebazaa
Alexandre Mebazaa
GSGianluigi Savarese
Gianluigi Savarese
GCGad Cotter
Gad Cotter
Acute heart failure with preserved ejection fraction (acute heart failure–heart failure with preserved ejection fraction) is increasingly prevalent, resulting from the interaction between a dysfunctional ventricle, the patient’s comorbidity burden and acute triggers. Patients are typically older, commonly female and have cardiometabolic, renal, arrhythmic, ischaemic and inflammatory comorbidities that produce vulnerability to decompensation. Acute episodes manifest with pulmonary and/or systemic congestion, from abrupt rises in left-sided filling pressures due to cardiac and arterial stiffness driven by neurohormonal activation and inflammation. Congestion and elevated blood pressure are common, but clinical presentation is more heterogeneous, reflecting the haemodynamic abnormalities, severity of triggers and comorbidity load. Diagnosis relies on integrating clinical context, echocardiography, adjusted thresholds of natriuretic peptides, and invasive and/or stress haemodynamics when diagnosis is uncertain. Management requires individualised decongestion, alongside treatment of precipitants. Early initiation of disease-modifying therapies after haemodynamic stability, including sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists, improves outcomes. Acute heart failure–heart failure with preserved ejection fraction follows a relapsing–remitting trajectory, underscoring the importance of comorbidity management, structured follow-up and preventive strategies.

13 May 2026 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
OCOvidiu Chioncel
Ovidiu Chioncel
AMAlexandre Mebazaa
Alexandre Mebazaa
SCSean P Collins
Sean P Collins
GCGad Cotter
Gad Cotter
BBBiykem Bozkurt
Biykem Bozkurt
MMMarco I. Metra
Marco I. Metra
There is a large spectrum of acute decompensated heart failure presentations resulting from the interaction between an acute precipitant and the patient’s underlying cardiac and non-cardiac conditions. A robust classification scheme at admission is crucial for appropriate triage and targeted treatment of high-risk populations. Such a scheme should incorporate timely actionable items to generate immediate management decisions, including characteristics that suggest life-threatening clinical presentations, the factors that could be favourably modified by in-hospital interventions, such as correctable aetiologies and congestion/hypoperfusion status, and in-hospital trajectories determined by patient responses to inpatient treatment. In-hospital trajectories determine the intensity of escalation therapies and timing for initiation/up-titration of guideline-directed medical treatment. In the long term, some patients experience a progressive downsloping course culminating in advanced heart failure, while others maintain a relatively stable remitting-relapsing trajectory. For future clinical trials, a comprehensive classification scheme integrating in-hospital and long-term trajectories could profoundly affect study design by ensuring interventions are tested in more homogeneous patient populations and facilitating nuanced patient stratification.

7 November 2025 in Heart Failure Reviews
Verified
Journal Article
Open access
PDF file
OGOLIVIANA GEAVLETE
OLIVIANA GEAVLETE
SCSean P. Collins
Sean P. Collins
AMAlexandre Mebazaa
Alexandre Mebazaa
LYLinda Ye
Linda Ye
APAlberto Palazzuoli
Alberto Palazzuoli
OCOvidiu Chioncel
Ovidiu Chioncel

14 July 2026 in Cardiac Failure Review
Verified
Journal Article
Open access
OGOLIVIANA GEAVLETE
OLIVIANA GEAVLETE
AAAndrew P Ambrosy
Andrew P Ambrosy
AMAlexandre Mebazaa
Alexandre Mebazaa
SCSean P Collins
Sean P Collins
JBJan Biegus
Jan Biegus
VIVlad Anton Iliescu
Vlad Anton Iliescu
Acute heart failure (AHF) is a systemic condition characterised by multiorgan involvement that varies from subclinical to overt organ failure. The liver is particularly vulnerable due to its dual blood supply and sensitivity to haemodynamic and inflammatory disturbances. Abnormal liver function tests are highly prevalent in patients with AHF, reflecting major mechanisms: passive hepatic venous congestion from elevated central venous pressure, hepatocellular ischaemia from low cardiac output, systemic inflammation and poor metabolic status associated with cachexia. In patients with AHF, liver function tests at admission, during hospitalisation and at discharge are independently associated with rehospitalisation, cardiovascular and all-cause mortality. Persistent abnormalities after hospitalisation often reflect incomplete decongestion or irreversible structural liver changes. Therapeutic strategies focus on decongestion, optimisation of cardiac output and medication adjustments to avoid hepatotoxicity. Despite significant advances in understanding cardio-hepatic interactions, major gaps remain, including the lack of standardised definitions, limited mechanistic studies and the underrepresentation of patients with heart failure with preserved ejection fraction in contemporary research. Future research should explore targeted therapies to improve cardiohepatic interactions and patient outcomes.